DeepMed Research

FONDAZIONE ITALIANA LINFOMI - ETS

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

Conditions: Non-Hodgkin Lymphoma, B-cell

Interventions: Drug: "novel" MAB (alone or in combination)

First Posted Date: 2023-08-23

Last Posted Date: 2024-12-30

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 1500

Registration Number: NCT06008691

Locations: 🇮🇹
Istituto Oncologico del Mediterraneo SPA - Oncologico, Viagrande, Catania, Italy
🇮🇹
Ospedale SS. Cosma e Damiano - Ospedale San Jacopo - SOS Oncoematologia ed ematologia clinica, Pescia, Pistoia, Italy
🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia, Alessandria, Italy

and more 55 locations

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Tislelizumab

First Posted Date: 2023-08-04

Last Posted Date: 2024-12-09

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 28

Registration Number: NCT05977673

Locations: 🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia, Alessandria, IT, Italy
🇮🇹
Divisione di Oncologia e dei Tumori immuto-correlati, Centro Di Riferimento Oncologico Di Aviano, Aviano, Italy
🇮🇹
Istituto di Ematologia L. e A. Seràgnoli, AOU Policlinico S. Orsola-Malpighi, Bologna, Italy

and more 7 locations

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase 2

Withdrawn

Conditions: Diffuse Large B Cell Lymphoma Refractory
Diffuse Large B-cell Lymphoma Recurrent

Interventions: Drug: R-DHAP
Drug: Pola-R-DHAP

First Posted Date: 2023-07-28

Last Posted Date: 2024-05-21

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Registration Number: NCT05966233

Locations: 🇮🇹
ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia, Milano, Italy
🇮🇹
P.O. Spirito Santo di Pescara, UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi, Pescara, Italy
🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia, Alessandria, Italy

and more 34 locations

Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Not Applicable

Recruiting

Conditions: Classical Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma (DLBCL)
Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Interventions: Behavioral: Lifestyles Implemented-Survivorship Care Plan (LS-SCP)

First Posted Date: 2023-07-06

Last Posted Date: 2024-12-31

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 552

Registration Number: NCT05934084

Locations: 🇮🇹
Ancona - AOU Ospedali Riuniti - Clinica di Ematologia, Ancona, Italy
🇮🇹
Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati, Aviano, Italy
🇮🇹
Istituto Tumori Bari Giovanni Paolo II, U.O. di Ematologia e Terapia Cellulare, Bari, Italy

and more 37 locations

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Phase 3

Recruiting

Conditions: Follicular Lymphoma

Interventions: Radiation: Radiotherapy
Other: Radiotherapy plus Obinutuzumab

First Posted Date: 2023-07-03

Last Posted Date: 2024-12-24

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 190

Registration Number: NCT05929222

Locations: 🇮🇹
Azienda Ospedaliera Nazionale Ss Antonio E Biagio E C Arrigo, SCDU Ematologia, Alessandria, Italy
🇮🇹
AORN San Giuseppe Moscati Avellino, U.O.C. Ematologia e Trapianto Emopoietico, Avellino, Italy
🇮🇹
Centro Di Riferimento Oncologico Di Aviano, S.O.C. Oncologia Medica e dei Tumori Immunocorrelati, Aviano, Italy

and more 45 locations

Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting

Conditions: Primary Cardiac Lymphoma

First Posted Date: 2023-04-19

Last Posted Date: 2025-01-01

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 43

Registration Number: NCT05819528

Locations: 🇮🇹
Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia, Pagani, Salerno, Italy
🇮🇹
AOU di Sassari - Ematologia, Sassari, SS, Italy
🇮🇹
Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia, Trieste, TS, Italy

and more 14 locations

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting

Conditions: Follicular Lymphoma

Interventions: Diagnostic Test: EZH2 mutations/CNAs by droplet digital PCR (ddPCR)
Diagnostic Test: EZH2-derived gene expression signature by RNA-Seq

First Posted Date: 2023-04-18

Last Posted Date: 2024-12-30

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 654

Registration Number: NCT05816850

Locations: 🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia, Alessandria, Italy
🇮🇹
Nuovo Ospedale degli Infermi, SSD Ematologia, Biella, Italy
🇮🇹
ASST Spedali Civili di Brescia - Ematologia, Brescia, Italy

and more 23 locations

Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting

Conditions: Low Grade Non-Hodgkin's Lymphoma, Adult

First Posted Date: 2022-09-01

Last Posted Date: 2024-12-31

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 150

Registration Number: NCT05524298

Locations: 🇮🇹
S.C. Ematologia - A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹
Clinica di Ematologia - A.O.U. Ospedali Riuniti, Ancona, Italy
🇮🇹
Divisione di Oncologia e dei Tumori immuno-correlati - IRCCS Centro di Riferimento Oncologico di Aviano, Aviano, Italy

and more 16 locations

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Phase 1

Recruiting

Conditions: Relapsed or Refractory Hodgkin's Lymphoma

Interventions: Drug: Atezolizumab
Combination Product: BEGEV

First Posted Date: 2022-03-29

Last Posted Date: 2024-12-31

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 122

Registration Number: NCT05300282

Locations: 🇮🇹
Ematologia - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Turin, Italy
🇮🇹
S.C. Ematologia - A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹
S.C. Ematologia e Trapianto emopoietico - Azienda Ospedaliera S.Giuseppe Moscati, Avellino, Italy

and more 18 locations

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Phase 2

Recruiting

Conditions: Refractory Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma

Interventions: Drug: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
Drug: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)

First Posted Date: 2022-02-22

Last Posted Date: 2025-01-01

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 49

Registration Number: NCT05249959

Locations: 🇮🇹
S.C. di Ematologia - A.O. S. Croce e Carle, Cuneo, Italy
🇮🇹
Divisione di Ematologia - A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy
🇮🇹
Divisione di Ematologia - IRCCS Policlinico S. Matteo di Pavia, Pavia, Italy

and more 18 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy